Alto Neuroscience vs Annovis Bio
ANRO and ANVS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANRO and ANVS compare
Alto Neuroscience is the larger company, worth 29 times as much as Annovis Bio ($1.2B against $39.5M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANRO | ANVS |
|---|---|---|
| Size and price | ||
| Market cap | $1.2B | $39.5M |
| Share price | $29.54 | $0.926 |
| Change, 1 year | 108% | −61.9% |
| Change, 5 years | – | −96.6% |
| Beta (5Y) | 1.86 | 1.95 |
| Employees | 68 | 8 |
| StockData Score | ||
| Total score | 4 | 4 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 3 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 3.9× | – |
| FCF yield | −6.9% | – |
| Profitability | ||
| Return on equity | −46.6% | – |
| Financial health | ||
| Debt / equity | 0.05 | – |
| Interest coverage | −48.5× | – |
| Current ratio | 18.12 | – |
| Altman Z-score | 22.11 (better) | −86.45 |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 75.1% | 25.5% |
| Held by insiders | 5.6% | 23.1% |
| Insider net buying, 12 months | −$3.6M | $6.8M (better) |
| Short interest, % of float | 15.3% | 16.3% |
Go deeper
- ANRO stock overview
- ANRO income statement
- ANRO valuation and score
- ANVS stock overview
- ANVS income statement
- ANVS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.